Boston Scientific's board approved a global restructuring plan on July 21 that is expected to begin in 2026 and be substantially complete by the end of 2029, with supply-chain changes, production transfers and organizational changes among the planned work. [1] [2]

The company estimates $700 million to $800 million in pretax charges, including $600 million to $700 million in future cash outlays, and expects gross annual pretax expenses to fall by about $500 million as benefits are realized. [1] [2]

Those figures describe three different ledgers rather than one saving: estimated accounting charges are not cash already paid, future cash is not a completed transfer, and an expected annual reduction is not money retained before implementation.

Reuters says some job losses are expected [1], while the SEC filing also says jobs will be created in growth areas [2]; neither source identifies affected workers, sites, severance, transfer schedules or service consequences, and much of the anticipated saving is meant for reinvestment.

With no verified X status recovered, the record supports neither a completed layoff count nor a delivered efficiency victory; it supports a board-approved four-year plan whose charges, cash payments, moves, gross savings, reinvestment and final net benefit must each be measured later over its planned duration.

-- PRIYA SHARMA, Delhi